Clinical Applicability of Multi-Tumor Marker Protein Chips for Diagnosing Ovarian Cancer

Bian, Jing; Li, Bo; Kou, Xianjuan; Wang, Xuna; Sun, Xiaoxu; Ming, Liang

doi:10.7314/apjcp.2014.15.19.8409

Cited by 14 publications

(10 citation statements)

References 10 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EOC is considered to be a silent killer because of its insidious onset and nonspecific early symptoms, thus it is always undiagnosable until advanced stages (Russell et al, 2014;Gasparri et al, 2015). Primary cytoreductive surgery aims at removing as much primary and metastatic tumor as possible in order to facilitate response to subsequent chemotherapy and improve survival (Gadducci et al, 2013;Bian et al, 2014). Currently, cisplatin and paclitaxel based chemotherapy combined with cytoreduction is the main clinical strategy for EOC, but is limited by high recurrence with a rate of approximately 70% and chemoresistance in platinum and paclitaxel resistant tumors (Rai et al, 2014.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells

Patel

Singh²,

Kumar³

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells

Patel

Singh²,

Kumar³

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…CA125 as a single marker showed good performance in ovarian cancer detection (AUC = 0.799), but with low sensitivity in ovarian cancer detection model (Yang, Lu, & Bast, ). To overcome the limitation of single marker in ovarian cancer detection, combined detection of multi‐tumor markers has been suggested (Bian et al, ). In this study, we found a panel of eight serum tumor markers showing improved performance in ovarian cancer detection (AUC = 0.873) than single CA125 marker.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients

Deng

Chen

Guo

et al. 2019

Molec Gen & Gen Med

View full text Add to dashboard Cite

Background The serum tumor markers has been widely used in ovarian cancer diagnosis. BRCA1/2 germline mutations are the most common predisposing factors for ovarian cancer development. This study aimed to comprehensively investigate serum tumor markers and BRCA1/2 germline mutations and analyze their associations with ovarian cancer. Methods Levels of 11 serum tumor markers were examined in ovarian cancer patients and controls with benign gynecologic diseases. By integrating multiplex PCR and next‐generation sequencing technologies, BRCA1/2 germline mutations were analyzed and confirmed by Sanger sequencing. The discriminative models with serum tumor markers and BRCA1/2 mutation status were constructed for ovarian cancer detection and patient stratification. Results Among 11 markers, six of them were significantly elevated and only beta‐human chorionic gonadotropin (β‐HCG) was significantly reduced in ovarian cancer patients. A total of 54 (23.3%) ovarian cancer patients were found to harbor BRCA1/2 deleterious mutations, and BRCA1/2 mutations were significantly associated with Hereditary Breast and Ovarian Cancer‐related tumors and family history of cancer. Carbohydrate antigen 125 showed a good performance in ovarian cancer detection as a single marker (AUC = 0.799), while a panel of eight markers showed a good performance in BRCA1 mutation detection with an AUC value of 0.974. In addition, a panel of five serum tumor markers combined with BRCA1/2 mutation status showed a good performance in lymph node metastasis prediction (AUC = 0.843). Conclusions We found the association between BRCA1/2 germline mutation status and serum tumor marker levels, and identified discriminative models that combined serum tumor markers with BRCA1/2 mutation status for ovarian cancer detection and patient stratification.

show abstract

“…The plasma samples were submitted to the Chongqing Cancer Hospital to test the serum tumor markers. Multi-tumor markers protein chip diagnose system was used to detect nine tumor markers in nude mouse colon cancer xenograft and negative control (NC) group, and further analysis was undertaken based on the results 50 .…”

Section: Methodsmentioning

confidence: 99%

Coptisine from Rhizoma Coptidis Suppresses HCT-116 Cells-related Tumor Growth in vitro and in vivo

Huang

Xiao

Lin

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Colorectal cancer is one of the most common causes of cancer-related death in humans. Coptisine (COP) is a natural alkaloid from Coptidis Rhizoma with unclear antitumor mechanism. Human colon cancer cells (HCT-116) and xenograft mice were used to systematically explore the anti-tumor activity of COP in this study. The results indicated that COP exhibited remarkably cytotoxic activities against the HCT-116 cells by inducing G1-phase cell cycle arrest and increasing apoptosis, and preferentially inhibited the survival pathway and induced the activation of caspase proteases family of HCT-116 cells. Experimental results on male BALB/c nude mice confirmed that orally administration of COP at high-dose (150 mg/kg) could suppress tumor growth, and may reduce cancer metastasis risk by inhibiting the RAS-ERK pathway in vivo. Taken together, the results suggested that COP may be potential as a novel anti-tumor candidate in the HCT-116 cells-related colon cancer, further studies are still needed to suggest COP for the further use.

show abstract

Clinical Applicability of Multi-Tumor Marker Protein Chips for Diagnosing Ovarian Cancer

Cited by 14 publications

References 10 publications

Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells

Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells

Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients

Coptisine from Rhizoma Coptidis Suppresses HCT-116 Cells-related Tumor Growth in vitro and in vivo

Contact Info

Product

Resources

About